Technology
Health
Biotechnology

TRACON Pharmaceuticals

$0.5111
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0209 (4.26%) As of 1:35 PM EDT today
+$0.0209 (4.26%) Today

Why Robinhood?

You can buy or sell TCON and other stocks, options, ETFs, and crypto commission-free!

About TCON

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. Read More The company was founded in October 2004 and is headquartered in San Diego, CA.

Employees
26
Headquarters
San Diego, California
Founded
2004
Market Cap
14.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
98.37K
High Today
$0.54
Low Today
$0.4903
Open Price
$0.50
Volume
20.94K
52 Week High
$2.35
52 Week Low
$0.40

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
2015 IPO
US
North America

TCON News

BenzingaAug 1

Tracon Pharma Shares Rally As First Patient Dosed In Cancer Trial

100

TCON Earnings

-$0.46
-$0.37
-$0.28
-$0.19
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.19 per share
Actual
-$0.21 per share

More TCON News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.